Trial Profile
A Phase 2, randomized, multiple-dose, double-blind, placebo-controlled safety and efficacy study of JKB-122 for the treatment of Non-Alcoholic Fatty Liver Disease (NAFLD)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 15 Oct 2020
Price :
$35
*
At a glance
- Drugs JKB 122 (Primary)
- Indications Fatty liver; Non-alcoholic fatty liver disease
- Focus Therapeutic Use
- 29 Aug 2020 Results presented at The International Liver Congress 2020
- 31 Oct 2018 New trial record
- 24 Oct 2018 Results presented in the TaiwanJ Pharmaceuticals media release.